|
1
|
Xavier RJ and Podolsky DK: Unravelling the
pathogenesis of inflammatory bowel disease. Nature. 448:427–434.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lewis JD: The utility of biomarkers in the
diagnosis and therapy of inflammatory bowel disease.
Gastroenterology. 140:1817–1826. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang YF, Ouyang Q and Hu RW: Progression
of inflammatory bowel disease in China. J Dig Dis. 11:76–82. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lahiff C, Safaie P, Awais A, et al: The
Crohn’s disease activity index (CDAI) is similarly elevated in
patients with Crohn’s disease and in patients with irritable bowel
syndrome. Aliment Pharmacol Ther. 37:786–794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alles VV, Bottazzi B, Peri G, Golay J,
Introna M and Mantovani A: Inducible expression of PTX3, a new
member of the pentraxin family, in human mononuclear phagocytes.
Blood. 84:3483–3493. 1994.PubMed/NCBI
|
|
6
|
Klouche M, Peri G, Knabbe C, Eckstein HH,
Schmid FX, Schmitz G and Mantovani A: Modified atherogenic
lipoproteins induce expression of pentraxin-3 by human vascular
smooth muscle cells. Atherosclerosis. 175:221–228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fazzini F, Peri G, Doni A, et al: PTX3 in
small-vessel vasculitides: an independent indicator of disease
activity produced at sites of inflammation. Arthritis Rheum.
44:2841–2850. 2001. View Article : Google Scholar
|
|
8
|
Baldini M, Maugeri N, Ramirez GA, et al:
Selective up-regulation of the soluble pattern-recognition receptor
pentraxin 3 and of vascular endothelial growth factor in giant cell
arteritis: relevance for recent optic nerve ischemia. Arthritis
Rheum. 64:854–865. 2012. View Article : Google Scholar
|
|
9
|
Lennard-Jones JE: Classification of
inflammatory bowel disease. Scand J Gastroenterol Suppl. 170:2–6.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benitez JM, Meuwis MA, Reenaers C, Van
Kemseke C, Meunier P and Louis E: Role of endoscopy,
cross-sectional imaging and biomarkers in Crohn’s disease
monitoring. Gut. 62:1806–1816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mantovani A, Valentino S, Gentile S,
Inforzato A, Bottazzi B and Garlanda C: The long pentraxin PTX3: a
paradigm for humoral pattern recognition molecules. Ann NY Acad
Sci. 1285:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kunes P, Holubcova Z, Kolackova M and
Krejsek J: Pentraxin 3(PTX 3): an endogenous modulator of the
inflammatory response. Mediators Inflamm. 2012:9205172012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kusnierz-Cabala B, Gurda-Duda A, Dumnicka
P, Panek J, Pawlica-Gosiewska D, Kulig J and Solnica B: Plasma
pentraxin 3 concentrations in patients with acute pancreatitis.
Clin Lab. 59:1003–1008. 2013.PubMed/NCBI
|
|
14
|
Bottazzi B, Doni A, Garlanda C and
Mantovani A: An integrated view of humoral innate immunity:
pentraxins as a paradigm. Annu Rev Immunol. 28:157–183. 2010.
View Article : Google Scholar
|
|
15
|
Sjöberg B, Qureshi AR, Anderstam B,
Alvestrand A and Bárány P: Pentraxin 3, a sensitive early marker of
hemodialysis-induced inflammation. Blood Purif. 34:290–297. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin Q, Fu F, Shen L and Zhu B: Pentraxin 3
in the assessment of ventilator-associated pneumonia: an early
marker of severity. Heart Lung. 42:139–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hudzik B, Szkodzinski J, Pietka-Rzycka A,
et al: Plasma pentraxin 3 may be a more sensitive marker of
inflammatory response than high-sensitivity C-reactive protein
after bare-metal stent compared to drug-eluting stent implantation.
J Interferon Cytokine Res. 33:280–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
